발간보고서
home > 자료실> 발간보고서
- 글자크기
Good Manufacturing Practices complementary to Experimental Drugs(ANVISA- BRAZIL)
| 작성자 | 관리자 | 카테고리 | 전문가 인사이트 |
|---|---|---|---|
| 작성일 | 2020-01-20 | 조회수 | 4,075 |
| 원문 | 한국보건산업진흥원 | ||
| 출처 | |||
| 첨부파일 | |||
Good Manufacturing Practices Complementary to Experimental Drugs.pdf(120.28KB)-원문제목 : Guide for Good Manufacturing Practices complementary to Experimental Drugs, according to ANVISA- BRAZIL
-Abstract : This Normative Instruction is intended to adopt the Good Practice Guidelines for the Manufacturing of Experimental Drugs from the Pharmaceutical Inspection Cooperation Scheme, PIC/S, as complementary requirements to be followed in the manufacture of experimental drugs in addition to the General Good Practice Guidelines for Drug Manufacturing.
* 첨부파일 참고 바랍니다.
- 이전글 Good Practices on Drug Distribution, Storage and Transportation(ANVISA- BRAZIL)
- 다음글 2019 바이오안전성백서
